Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

ally fluctuate between periods of intense disease activity, during which the patient's own immune system is actively attacking and causing damage in their kidney, and periods of remission. Aspreva estimates that there are about 600,000 diagnosed lupus nephritis patients worldwide. There have been no new approved treatment options for SLE or lupus nephritis in the United States in over forty years. Current induction treatments involve the off-label use of existing cancer drugs such as cyclophosphamide, steroids, and immunosuppressants such as azathioprine. These treatments can also have life-threatening side effects that can be worse than the disease itself. Since the disease is more prevalent in women and tends to manifest itself when they are of child-bearing age, drugs that adversely affect fertility can also compound the negative impact of the disease on a patient's quality of life.

More About the Aspreva Lupus Nephritis Study

Aspreva's lupus nephritis study is one of the largest phase III studies ever conducted in lupus nephritis. This two-phase induction to maintenance study was designed as a randomized open label comparison of mycophenolate mofetil (MMF) with cyclophosphamide for the first six months (induction phase), followed by a double-blind comparison of MMF to azathioprine for up to three years (maintenance phase). Treatment response in the induction phase of this trial was defined as a decrease in proteinuria and the stabilization or improvement of serum creatinine. The first patient of this study was treated in July 2005 and patient enrollment was completed at the end of September, 2006. Re-randomization to the maintenance phase is complete and this phase of the study is ongoing. It is important to note that MMF is not currently approved by the FDA for the treatment of any autoimmune disease.

Conference Call

Aspreva will host a conference call to discuss results on Wednesday, June 27, 2007 at 9:30 a.m. ET (6:30 a.m. PT).


'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
(Date:7/30/2015)... 30, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese medicine ... updates regarding the notice it received on May 21, ... that the Company was below certain of the Exchange,s ... and 1101 of the NYSE MKT Company Guide, due ...
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced ... (MAA) with the European Medicines Agency (EMA) for lorcaserin, ... weight loss and maintenance of weight loss, in patients ... overweight (BMI >27) and have at least one weight-related ...
... Corporation (NASDAQ: IRIX ) today announced that ... conferences this month. The Company presents today ... Conference where President and CEO Dominik Beck will host ... the day.  The Company is also ...
Cached Medicine Technology:Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 2Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 3Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 4
(Date:7/31/2015)... ... ... According to WFLA on July 16th, Sarasota has seen at least ... deaths have held steady over the last “couple of months” according to WFLA. Law ... spurred by the crackdown of prescription painkillers. Many users who were addicted to prescription ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Practice, and Hospital Medicine Practice, is pleased to announce that it has partnered ... application format available on iPhones, iPads, and Android smartphones and tablets. , ...
(Date:7/31/2015)... ... 2015 , ... An article entitled " Dentists Doing Dermatology? ... unfortunate experience having cosmetic skin procedures done by a family doctor not board-certified ... bruising, and pain. This woman’s experience is only one in a series of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... of a wide variety of nutritional and wellness products, announced the addition of ... specializes in massage therapy, active isolated stretching and the prevention and rehabilitation of ...
(Date:7/31/2015)... ... 31, 2015 , ... People love to feel like they ... price is an important factor to clients when choosing to purchase a policy. ... Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. , ...
Breaking Medicine News(10 mins):Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2
... fear and anxiety are involved, and the amygdalathe brain,s almond-shaped ... But the amygdala doesn,t do its job alone. Scientists at ... the fear map to part of the brain known as ... MD, PhD, found that mice lacking a critical growth factor ...
... scientists at Carnegie Mellon University,s Language Technologies Institute (LTI) ... on Haitian Creole so that translation tools desperately needed ... earthquake-ravaged island can be rapidly developed. Since Carnegie Mellon ... a team at Microsoft Research has used it to ...
... ... ... HealthWorks Medical Group, a leading nationwide operator of on-the-job-injury health and urgent care centers, today ... by getting workers vaccinated against H1N1., , , , ,“U.S. HealthWorks wants to send our ...
... mice ,rejuvenated, when treated with blood factors from younger mice, ... have found a way to make old stem cells in ... could lead to ways to slow the aging process. , ... putting them in old mice made old stem cells take ...
... stem cell therapy, but much research remains to be ... at Stanford University have succeeded in creating brain nerve ... tails of adult mice. , The new approach could ... how cells choose and maintain their specialized roles in ...
... ... Vice Chairwoman, Stephanie DeKemper takes ownership. , ... Indianapolis, IN (PRWEB) Jan. 27, 2010 -- SynCare, LLC ( www.syncarellc.com ) announced ... of Directors Vice Chairwoman Stephanie DeKemper. , , , , ,An aggressive and well-respected consumer ...
Cached Medicine News:Health News:Brain scientists extend map of fear memory formation 2Health News:Carnegie Mellon releases data on Haitian Creole to hasten development of translation tools 2Health News:Twitter Contest: Free, Onsite H1N1 Vaccination Day for Winning Businesses 2Health News:Aging of Blood Stem Cells May Be Reversible 2Health News:Scientists Turn Mouse Skin Cells Into Nerve Cells 2Health News:Scientists Turn Mouse Skin Cells Into Nerve Cells 3Health News:SynCare, LLC Completes Sale of Assets to Stephanie DeKemper 2Health News:SynCare, LLC Completes Sale of Assets to Stephanie DeKemper 3
... Microalbumin Strips provide albumin, creatinine and albumin-to-creatinine ... Microalbumin product is useful to test for ... in order to detect early kidney disease. ... the urinary albumin excretion rate, is an ...
... to near-patient urinalysis. The Chemstrip ... affordable, reliable alternative to visual ... fundamental, easy-to-use features, the Chemstrip ... office lab, clinic, and hospital ...
... UA is the first hand-held urine ... valuable lab bench space. Automation of ... in results between operators and transcription ... run, corrects for ambient temperature and ...
... first outside-the-balloon, dual-wire dilatation catheter. The ... innovative new approach to dilatation. Its unique, ... wires to create expansion planes at low ... ,The FX miniRAIL RX PTCA Catheter is ...
Medicine Products: